MedPath

Short Duration Treatment of Non-severe Community Acquired Pneumonia

Phase 2
Conditions
Community Acquired Pneumonia
Interventions
Radiation: Chest X-ray
Biological: blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry
Drug: Placebo (for Augmentin)
Drug: Beta-Lactams
Registration Number
NCT01963442
Lead Sponsor
Versailles Hospital
Brief Summary

To investigate the non inferiority of a short lasting antibiotic treatment (3 days) when compared to a long lasting antibiotic treatment (8 days), at Day 15 after the beginning of treatment in terms of clinical efficacy, in adults admitted to emergency services for a non severe Community Acquired Pneumonia (PAC), who responded well to 3 days of beta-lactamin treatment (3GC or A/AC).

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
310
Inclusion Criteria
  • Subject must be 18 years old or over.
  • admitted three days before for Community Acquired Pneumonia (CAP) defined by at least one clinical sign of pneumonia (dyspnea, cough, mucopurulent sputum, crackling sound on lungs) associated with a temperature >38°C on admission, and a new infiltrate consistent with pneumonia on chest x-ray, who responded favorably to 3 days of treatment with β-lactams (third generation injectable cephalosporin or amoxicillin-clavulanate)
  • able to take oral medication.
  • has given its informed consent.
Exclusion Criteria
  • Creatinin < 30ml/min
  • History of jaundice / hepatic impairment associated with amoxicillin / clavulanic acid
  • History of hypersensitivity to beta-lactam
  • Presence of complications or severity of pneumonia (abscess , significant pleural effusion, severe chronic respiratory failure , septic shock, respiratory condition requiring the passage resuscitation).
  • Known immunocompromised terrain ( asplenia , neutropenia, agammaglobulinemia , immunosuppressants, graft corticosteroids , myeloma , lymphoma, known HIV , sickle cell anemia , CHILD C cirrhosis).
  • Antibiotic treatment exceeding 24 hours prior admission.
  • Suspected atypical bacteria requiring combined antibiotics therapy .(Subjects who received a single dose of macrolides or fluoroquinolones emergency will not be excluded) .
  • Legionella suspected on clinical, biological and radiological criteria .
  • Subjects with clinical or epidemiological environment leading to suspect a healthcare-associated pneumonia with antibiotic resistant pathogen.
  • Suspicion of pneumonia by aspiration.
  • Intercurrent infection requiring antibiotic treatment.
  • Pregnant women .
  • Breastfeeding .
  • Allergy to antibiotics in use.
  • Life expectancy <1 month .
  • Subject without health insurance.
  • Subjects without home adress

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Amoxicillin/Clavulanic acid treatmentChest X-rayafter 3 day treatment of β-lactams, the subjects receive 5-day treatment of Amoxicillin/clavulanic acid. Chest X-ray performed at admission and Day 30 and replapses. 'blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
Amoxicillin/Clavulanic acid treatmentblood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistryafter 3 day treatment of β-lactams, the subjects receive 5-day treatment of Amoxicillin/clavulanic acid. Chest X-ray performed at admission and Day 30 and replapses. 'blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
Amoxicillin/Clavulanic acid treatmentAugmentinafter 3 day treatment of β-lactams, the subjects receive 5-day treatment of Amoxicillin/clavulanic acid. Chest X-ray performed at admission and Day 30 and replapses. 'blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
Amoxicillin/Clavulanic acid treatmentBeta-Lactamsafter 3 day treatment of β-lactams, the subjects receive 5-day treatment of Amoxicillin/clavulanic acid. Chest X-ray performed at admission and Day 30 and replapses. 'blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
placebo treatmentChest X-rayafter 3-day treatment of β-lactams, the subjects receive 5-day treatment of placebo. Chest X-ray performed at admission and Day 30 and replapse. blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
placebo treatmentblood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistryafter 3-day treatment of β-lactams, the subjects receive 5-day treatment of placebo. Chest X-ray performed at admission and Day 30 and replapse. blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
placebo treatmentPlacebo (for Augmentin)after 3-day treatment of β-lactams, the subjects receive 5-day treatment of placebo. Chest X-ray performed at admission and Day 30 and replapse. blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
placebo treatmentBeta-Lactamsafter 3-day treatment of β-lactams, the subjects receive 5-day treatment of placebo. Chest X-ray performed at admission and Day 30 and replapse. blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
Primary Outcome Measures
NameTimeMethod
clinical evaluation at Day 15Day 15

Clinical evaluation at Day 15 composed of the composite measure of the Clinical examination for clinical symptoms of CAP, recording of the body temperature and confirmation that no additionnal antibiotic treatment was required from Day 8

Secondary Outcome Measures
NameTimeMethod
clinical evaluation at Day 30Day 30

Clinical evaluation at Day 30 composed of the composite measure of the Clinical examination for clinical symptoms of CAP, recording of the body temperature and Evaluation of replapse or aggravation of pneumonia or any other respiratory infections in subjects considered cured at Day 15.

Trial Locations

Locations (20)

Foch Hospital

🇫🇷

Suresnes, France

CH Versailles

🇫🇷

Le Chesnay, France

CHI Creteil

🇫🇷

Creteil, France

CH Beaujon

🇫🇷

Clichy, France

CHU Rennes Pontchaillou

🇫🇷

Rennes, France

CHU Ambroise Paré

🇫🇷

Boulogne-Billancourt, France

CH Argenteuil

🇫🇷

Argenteuil, France

CH d'Annecy Genevois

🇫🇷

Metz-Tessy, France

Central Hospital Raymon Poincaré

🇫🇷

Garches, France

CH Bicêtre

🇫🇷

Le Kremlin Bicètre, France

CHU de Grenoble

🇫🇷

La Tronche, France

Melun Hospital

🇫🇷

Melun, France

CH Lariboisière

🇫🇷

Paris, France

CHU Saint Antoine

🇫🇷

Paris, France

CHU Cochin

🇫🇷

Paris, France

CHU Bichat

🇫🇷

Paris, France

CH Tenon

🇫🇷

Paris, France

CH Pontoise

🇫🇷

Pontoise, France

CH Saint Denis

🇫🇷

Saint Denis, France

CHU Rouen

🇫🇷

Rouen, France

© Copyright 2025. All Rights Reserved by MedPath